Lv7
3230 积分 2026-02-02 加入
Current State of Evidence on Definitions and Management of High-Risk Multiple Myeloma
6小时前
已完结
European Myeloma Network Consensus Statement on Functional High‐Risk Multiple Myeloma
7小时前
已完结
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma
7小时前
已完结
A guide to CAR T cell therapies: development, current status and future prospects
5天前
已完结
Impact of Treatment Sequencing with CAR T-cell Therapies and Bispecific Antibodies on Long-term Survival in 4L+ RRMM in the United States: A Simulation Model
10天前
已完结
Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy
10天前
已完结
A safe and potent anti-CD19 CAR T cell therapy
15天前
已完结
Prognostic Significance of Absolute Lymphocyte Count (ALC) and Lymphodepletion (LD) Regimen in Chimeric Antigen Receptor T-cell Therapy (CAR T)
15天前
已完结
IMWG consensus on risk stratification in multiple myeloma
27天前
已完结
Camelid single-domain antibodies: A versatile tool for in vivo imaging of extracellular and intracellular brain targets
1个月前
已完结
皖公网安备34019202002308
